New long acting β2 agonists: Expert Opinion on Therapeutic Patents: Vol 13, No 2

Views

CrossRef citations to date

Altmetric

Abstract

Two applications claiming novel long-acting β₂ agonists provide new analogues of salmeterol and formoterol, respectively. The first claims salmeterol derivatives in which the terminal phenyl group bears an imidazolidinedione substituent, the second combines the head group employed in formoterol with a sulfonamido substituted tail portion of salmeterol.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

New long acting β₂ agonists

Information for

Open access

Opportunities

Help and information

New long acting β2 agonists

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature

New long acting β₂ agonists